Distinct requirements for Ras oncogenesis in human versus mouse cells.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Genes & Development

• Publication date

  2002-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1101/GAD.993902PMID 12183360PMCID PMC186434
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation

  2002cited by this paper
• Involvement of Phosphatidylinositol 3-Kinase, but Not RalGDS, in TC21/R-Ras2-mediated Transformation*

  2002cited by this paper
• Somatic activation of the K-ras oncogene causes early onset lung cancer in mice

  2001cited by this paper
• N-Terminal Domains of the Human Telomerase Catalytic Subunit Required for Enzyme Activity in Vivo

  2001cited by this paper
• A genetically tractable model of human glioma formation.

  2001cited by this paper
• Ras effectors: buying shares in Ras plc.

  2001cited by this paper
• Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells.

  2001cited by this paper
• Signal Pathways Which Promote Invasion and Metastasis: Critical and Distinct Contributions of Extracellular Signal-Regulated Kinase and Ral-Specific Guanine Exchange Factor Pathways

  2001cited by this paper
• Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells.

  2001cited by this paper
• A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.

  2000cited by this paper
• PIK3CA as an oncogene in cervical cancer

  2000cited by this paper
• Understanding Ras: 'it ain't over 'til it's over'.

  2000cited by this paper
• PI3-kinase inhibition: a target for drug development?

  2000cited by this paper
• RalGEF2, a Pleckstrin Homology Domain Containing Guanine Nucleotide Exchange Factor for Ral*

  2000cited by this paper
• Phospholipase D and RalA Cooperate with the Epidermal Growth Factor Receptor To Transform 3Y1 Rat Fibroblasts

  2000cited by this paper
• Identification and Characterization of a New Family of Guanine Nucleotide Exchange Factors for the Ras-related GTPase Ral*

  2000cited by this paper
• RAS inhibitors: potential for cancer therapeutics.

  2000influential reference
• Development of anticancer drugs targeting the MAP kinase pathway

  2000cited by this paper
• A novel RalGEF-like protein, RGL3, as a candidate effector for rit and Ras.

  2000cited by this paper
• Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene

  2000cited by this paper
• Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

  1999cited by this paper
• Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).

  1999cited by this paper
• Ras caught in another affair: the exchange factors for Ral.

  1999influential reference
• Creation of human tumour cells with defined genetic elements

  1999cited by this paper
• Ral-Specific Guanine Nucleotide Exchange Factor Activity Opposes Other Ras Effectors in PC12 Cells by Inhibiting Neurite Outgrowth

  1999influential reference
• Thermodynamic and Kinetic Characterization of the Interaction between the Ras Binding Domain of AF6 and Members of the Ras Subfamily*

  1999cited by this paper
• Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

  1999cited by this paper
• New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.

  1999cited by this paper
• Structure determination of the Ras-binding domain of the Ral-specific guanine nucleotide exchange factor Rlf.

  1998cited by this paper
• Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization.

  1998cited by this paper
• Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span.

  1998cited by this paper
• Extension of life-span by introduction of telomerase into normal human cells.

  1998cited by this paper
• Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation

  1998influential reference
• A Role for RalGDS and a Novel Ras Effector in the Ras-mediated Inhibition of Skeletal Myogenesis*

  1998cited by this paper
• Increased levels of phosphatidylinositol 3‐kinase activity in colorectal tumors

  1998cited by this paper
• Reversing time: origin of telomerase.

  1998cited by this paper
• Stimulation of gene induction and cell growth by the Ras effector Rlf

  1997influential reference
• Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras.

  1997influential reference
• rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral

  1997cited by this paper
• Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

  1997cited by this paper
• A survey of telomerase activity in human cancer.

  1997cited by this paper
• Tumors associated with p53 germline mutations: a synopsis of 91 families.

  1997cited by this paper
• Protein binding and signaling properties of RIN1 suggest a unique effector function.

  1997cited by this paper
• Ral‐GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation.

  1996influential reference
• Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

  1996cited by this paper
• A Role for the Ral Guanine Nucleotide Dissociation Stimulator in Mediating Ras-induced Transformation*

  1996influential reference
• Activation of phosphoinositide 3‐kinase by interaction with Ras and by point mutation.

  1996cited by this paper
• SV40 early region and large T antigen in human brain tumors, peripheral blood cells, and sperm fluids from healthy individuals.

  1996cited by this paper
• Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation

  1996cited by this paper
• Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells.

  1996cited by this paper
• Natural simian virus 40 strains are present in human choroid plexus and ependymoma tumors.

  1995cited by this paper
• An essential role for Rac in Ras transformation

  1995cited by this paper
• Multiple Ras functions can contribute to mammalian cell transformation.

  1995influential reference
• Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation

  1995cited by this paper
• Telomerase activity in normal and malignant murine tissues.

  1995cited by this paper
• Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene

  1995cited by this paper
• Activation of Raf as a result of recruitment to the plasma membrane.

  1994cited by this paper
• Tumour predisposition in mice heterozygous for a targeted mutation in Nf1

  1994cited by this paper
• Transformation of mammalian cells by constitutively active MAP kinase kinase.

  1994influential reference
• Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane

  1994cited by this paper
• Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases.

  1994cited by this paper
• Simian virus 40-like DNA sequences in human pleural mesothelioma.

  1994cited by this paper
• Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells.

  1994influential reference
• Identification of the sites in MAP kinase kinase‐1 phosphorylated by p74raf‐1.

  1994influential reference
• Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis

  1993cited by this paper
• Interactions between SV40 large‐tumor antigen and the growth suppressor proteins pRB and p53

  1993cited by this paper
• A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras.

  1993cited by this paper
• Functional analysis of the retinoblastoma gene product and of RB-SV40 T antigen complexes.

  1992cited by this paper
• DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood.

  1992cited by this paper
• Raf-1 activates MAP kinase-kinase

  1992cited by this paper
• Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

  1992cited by this paper
• Effects of an Rb mutation in the mouse

  1992cited by this paper
• Raf-1 protein kinase is required for growth of induced NIH/3T3 cells

  1991cited by this paper
• Guanine nucleotide binding properties of the mammalian RalA protein produced in Escherichia coli.

  1990influential reference
• Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A.

  1990cited by this paper
• Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.

  1990cited by this paper
• Transforming c-Ki-ras mutation is a preneoplastic event in mouse mammary carcinogenesis induced in vitro by N-methyl-N-nitrosourea

  1990cited by this paper
• ras oncogenes in human cancer: a review.

  1989influential reference
• Definition of the human raf amino-terminal regulatory region by deletion mutagenesis

  1989influential reference
• Structure and biological activity of human homologs of the raf/mil oncogene

  1985influential reference
• Genetic origin of mutations predisposing to retinoblastoma.

  1985cited by this paper
• Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats

  1985cited by this paper
• Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

  1982cited by this paper
• Role of small t antigen in the acute transforming activity of SV40.

  1982cited by this paper
• Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma.

  1980cited by this paper
• Dissociation of anchorage independence from tumorigenicity in human cell hybrids

  1980cited by this paper
• Mutants of SV40 with an altered small t protein are reduced in their ability to transform cells.

  1978cited by this paper

• Why isn't an oncogenic mutation in KRAS enough to induce and sustain transformation?

  2026cites this paper
• RALGEF inhibitors suppress RAS-driven pancreatic cancer and metastasis

  2025cites this paper
• A review and perspective paper: Ras oncogene gets modest, from kingpin to mere henchman

  2024cites this paper
• Мутации в генах KRAS/NRAS и эффективность индукционной терапии по трехкомпонентным схемам на основе бортезомиба у пациентов с впервые диагностированной множественной миеломой

  2024cites this paper
• Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?

  2024cites this paper
• Defining bone fide effectors of RAS GTPases

  2023cites this paper
• The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells.

  2023cites this paper
• Single-cell resolution reveals RalA GTPase expanding hematopoietic stem cells and facilitating of BCR-ABL1-driven leukemogenesis in a CRISPR/Cas9 gene editing mouse model

  2023cites this paper
• BRAFV600E-Driven Lung Adenocarcinoma Requires Copper to Sustain Autophagic Signaling and Processing

  2022cites this paper
• Betacellulin promotes tumor development and EGFR mutant lung cancer growth by stimulating the EGFR pathway and suppressing apoptosis

  2022cites this paper
• Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma

  2022cites this paper
• Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence

  2021cites this paper
• The RAL signaling network: Cancer and beyond.

  2021cites this paper
• Genetically Engineered Mouse Models of Esophageal Cancer.

  2021cites this paper
• Dissecting the Involvement of Ras GTPases in Kidney Fibrosis

  2021cites this paper
• Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities

  2021cites this paper
• RGL2 Drives the Metastatic Progression of Colorectal Cancer via Preventing the Protein Degradation of β-Catenin and KRAS

  2021cites this paper
• Regulation of GTPase function by autophosphorylation

  2021cites this paper
• Calmodulin extracts the Ras family protein RalA from lipid bilayers by engagement with two membrane-targeting motifs

  2021cites this paper
• Neural Architectures for Biological Inter-Sentence Relation Extraction

  2021cites this paper
• Targeting KRAS: The Elephant in the Room of Epithelial Cancers

  2021cites this paper
• The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease

  2020cites this paper
• Targeting Ras signaling in AML: RALB is a small GTPase with big potential

  2020cites this paper
• Dampened PI3K/AKT signaling contributes to cancer resistance of the naked mole rat

  2020cites this paper
• The three dimensions of somatic evolution: Integrating the role of genetic damage, life‐history traits, and aging in carcinogenesis

  2020cites this paper
• RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer

  2020cites this paper
• Affinity maturation of the RLIP76 Ral binding domain to inform the design of stapled peptides targeting the Ral GTPases

  2020cites this paper
• RASSF effectors couple diverse RAS subfamily GTPases to the Hippo pathway

  2020cites this paper
• Therapeutic peptides targeting the Ras superfamily

  2020cites this paper
• Therapeutic targeting of RAS: New hope for drugging the "undruggable".

  2020cites this paper
• Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAFV600E-Driven Melanoma

  2020cites this paper
• Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues

  2019cites this paper
• Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers

  2019cites this paper
• Developmental fidelity is imposed by genetically separable RalGEF activities that mediate opposing signals

  2019cites this paper
• A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors

  2019cites this paper
• Exploring the Tumor and Premetastatic Microenvironment of the Ovary

  2019cites this paper
• Localization of RalB signaling at endomembrane compartments and its modulation by autophagy

  2019cites this paper
• Ras signals principally via Erk in G1 but cooperates with PI3K/Akt for Cyclin D induction and S-phase entry

  2019cites this paper
• Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma

  2019cites this paper
• Regulation of Shaoyao Ruangan Mixture on Intestinal Flora in Mice With Primary Liver Cancer

  2019cites this paper
• Defining the importance of protein geranylgeranylation in innate immunity

  2018cites this paper
• Synthetic Lethal Interactions With Oncogenic KRAS

  2018cites this paper
• Developmental fidelity imposed by the RGL-1 “Balanced Switch” mediating opposing signals

  2018cites this paper
• Ral signals through a MAP4 Kinase-p38 MAP kinase cascade in C. elegans cell fate patterning

  2018cites this paper
• PI3K: A Crucial Piece in the RAS Signaling Puzzle.

  2018cites this paper
• Small GTPases.

  2018influential citation
• Translational Animal Models for Liver Cancer

  2018cites this paper
• RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer

  2018cites this paper
• RalGPS2 is involved in tunneling nanotubes formation in 5637 bladder cancer cells

  2018cites this paper
• Regulation of breast cancer biomarkers by intrinsic and extrinsic factors

  2018cites this paper
• Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.

  2018cites this paper
• RalB directly triggers invasion downstream Ras by mobilizing the Wave complex

  2018cites this paper
• The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma

  2018cites this paper
• Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability

  2018cites this paper
• Autoinhibition in Ras effectors Raf, PI3Kα, and RASSF5: a comprehensive review underscoring the challenges in pharmacological intervention

  2018cites this paper
• Clinical correlation of molecular (VEGF, FGF, PDGF, c-Myc, c-Kit, Ras, p53) expression in juvenile nasopharyngeal angiofibroma

  2018cites this paper
• Ral signaling pathway in health and cancer

  2017cites this paper
• The Pig as a Large Animal Model for Studying Anti-Tumor Immune Responses

  2017cites this paper
• Activation of Ras by Post-Translational Modifications

  2017cites this paper
• The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting.

  2017cites this paper
• IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis.

  2017cites this paper
• Regulation of Ras signaling and function by plasma membrane microdomains.

  2017cites this paper
• Quality Assurance Guided FISH-Analysis for Optimal Detection of AMLAssociated Chromosomal Aberrations

  2017cites this paper
• RalGPS2 interacts with LST1 and supports tunneling nanotubes formation in human bladder cancer cells

  2017cites this paper
• The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform

  2017cites this paper
• The Many Roles of Ral GTPases in Ras-Driven Cancer

  2017cites this paper
• Mechanisms of Resistance to MAPK Pathway Inhibition in RAS-Mutant Cancers

  2016cites this paper
• The discovery of a novel, Ras-mediated NORE1A/PMLIV tumor suppressor complex.

  2016cites this paper
• Ral-Arf6 crosstalk regulates Ral dependent exocyst trafficking and anchorage independent growth signalling

  2016cites this paper
• Molecular Mechanisms Regulating MYC and PGC1β Expression in Colon Cancer

  2016cites this paper
• Engineered Swine Models of Cancer

  2016influential citation
• Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release

  2016cites this paper
• DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets

  2016cites this paper
• Evaluating the therapeutic potential of the PAK1 and TBK1 kinases in pancreatic ductal adenocarcinoma

  2016cites this paper
• Mitochondrial clearance by the STK38 kinase supports oncogenic Ras-induced cell transformation

  2016cites this paper
• RalGPS2 Is Essential for Survival and Cell Cycle Progression of Lung Cancer Cells Independently of Its Established Substrates Ral GTPases

  2016cites this paper
• Clinical significance of serum autoantibodies against Ras-like GTPases, RalA, in patients with esophageal squamous cell carcinoma

  2016cites this paper
• Tyrosine phosphorylation of RalGDS by c-Met receptor blocks its interaction with Ras.

  2016cites this paper
• Repression of CD 24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI 3 K

  2015cites this paper
• RalB regulates contractility-driven cancer dissemination upon TGFβ stimulation via the RhoGEF GEF-H1

  2015cites this paper
• CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.

  2015cites this paper
• Ral GTPases: crucial mediators of exocytosis and tumourigenesis.

  2015cites this paper
• Tumorigenesis of the Epidermal Keratinocytes (the first part): -- Introducton --@@@―― 総論 ――

  2015cites this paper
• Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation

  2015cites this paper
• ICRP Publication 131: Stem Cell Biology with Respect to Carcinogenesis Aspects of Radiological Protection

  2015cites this paper
• The role of miR-200a in mammalian epithelial cell transformation.

  2015cites this paper
• The Exocyst at a Glance

  2015cites this paper
• Targeting the Ras-Ral effector pathway for cancer treatment

  2015cites this paper
• Regulation of the retinoblastoma tumor suppressor by the novel Ras effector NORE1A.

  2015cites this paper
• Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K

  2015cites this paper
• Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth.

  2015cites this paper
• Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models

  2015cites this paper
• Regulation of autophagy and chloroquine sensitivity by oncogenic RAS in vitro is context-dependent

  2014cites this paper
• The clinical development of MEK inhibitors

  2014cites this paper
• The study of RAS-induced metabolic reprogramming and the role of the pentose phosphate pathway in tumor metabolism

  2014cites this paper
• Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame.

  2014cites this paper
• A New Spontaneously Transformed Syngeneic Model of High-Grade Serous Ovarian Cancer with a Tumor-Initiating Cell Population

  2014cites this paper
• General aspects of protein prenylation The importance of FT and GGT 1 for normal physiology and tumorigenesis : lessons from knockout mice

  2014cites this paper
• Inhibiting protein clearance to induce cell death in tuberous sclerosis and pancreatic cancer

  2014cites this paper
• The Coordinated Biology and Signaling Partners of Ral G-Proteins

  2014cites this paper